Review anchor
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
CHEMBL3130
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform as ChEMBL target CHEMBL3130, mapped to UniProt O00329. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3130
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O00329
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform matters
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform is reviewed as Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (UniProt O00329); Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform shows approved-linked disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block.; 8 linked drugs keep this evidence frame grounded.; the current evidence base includes 14 approved drugs, 11769 compounds, and 913 assays, with lead potency reaching pChEMBL 10.7.
Protein context
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Sequence length is 1044 aa.
Review this target as Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform, mapped to UniProt O00329. Sequence length is 1044 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt O00329
Protein
Disease context
chronic lymphocytic leukemia
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform shows approved-linked disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AMG-319, COPANLISIB, DUVELISIB MONOHYDRATE.
Start review with chronic lymphocytic leukemia because it currently carries approved-linked support. Linked drugs include AMG-319, COPANLISIB, DUVELISIB MONOHYDRATE, IDELALISIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
8 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 14 approved drugs, 11769 compounds, and 913 assays for this target. The dominant activity type is IC50. CHEMBL1236962 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL1236962 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core Engine
14 approved
pChEMBL 10.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt O00329, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why chronic lymphocytic leukemia is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
11769
Total Compounds
913
Total Assays
14
Approved Drugs
IC50: 15059.0, KI: 296.0, EC50: 37.0, KD: 245.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1236962
|
10.7 | Ki | Clinical |
|
|
No preferred name
CHEMBL4441003
|
10.4 | IC50 | — |
|
|
No preferred name
CHEMBL5947580
|
10.4 | IC50 | — |
|
|
No preferred name
CHEMBL5806327
|
10.4 | IC50 | — |
|
|
No preferred name
CHEMBL3704739
|
10.3 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
INAVOLISIB
CHEMBL4650215
|
2024 |
|
|
LENIOLISIB
CHEMBL3643413
|
2023 |
|
|
UMBRALISIB
CHEMBL3948730
|
2021 |
|
|
ALPELISIB
CHEMBL2396661
|
2019 |
|
|
DUVELISIB
CHEMBL3039502
|
2018 |
|
|
COPANLISIB
CHEMBL3218576
|
2017 |
|
|
COPANLISIB HYDROCHLORIDE
CHEMBL3545068
|
2017 |
|
|
IDELALISIB
CHEMBL2216870
|
2014 |
Source Header